The company is developing LX214 as a potential treatment for keratoconjunctivitis sicca, commonly known as dry eye syndrome, and other chronic inflammatory ocular surface diseases. Lux has filed
Cubist said that this Phase I trial is the first time CB-182,804 has been given to humans and is designed to evaluate the safety and pharmacokinetics of CB-182,804
While the product meets all the FDA’s requirements for manufacturing quality, clinical safety and efficacy, the company must resolve certain patent issues related to the reference product, Ultram
According to the company, this is the first technology that has been cleared by the FDA to enhance polyp detection when used in conjunction with the gold standard
Proceeds from this financing will be used to continue to advance the clinical development of the company’s EndoBarrier gastrointestinal liner and endobarrier platform of medical devices for the
The price paid for the common stock is equal to the consolidated closing bid price on the Nasdaq global market on the day of pricing, February 13, 2009.
Dr Sheares is former CEO and member of the board of directors of Reliant Pharmaceuticals. Prior to joining Reliant, Dr Sheares was president of the US human health
Mr Borkowski will remain with the company until a successor is named and in place. Mylan has retained the executive recruitment firm Korn/Ferry International to lead the search
Conbriza, an investigational medicine, is in development by Wyeth Pharmaceuticals, a division of Wyeth. The efficacy of Conbriza was studied in two multicenter, double-blind, randomized Phase III clinical
Mr Kelley has over 20 years of senior executive experience including serving as the chairman of the board of directors, president and CEO of McDATA. Prior to joining
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.